Drugs / OmniMSC-AMI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05724576 | Jun 2023 → May 2026 | — | Taiwan Bio Therapeutics Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OmniMSC-AMI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05724576 ↗ |
| Modality | Cell therapy | “OmniMSC-AMI (allogenic bone marrow-derived mesenchymal stem cells)” NCT05724576 ↗ |
| Route | Other | “intracoronary administration of OmniMSC-AMI” NCT05724576 ↗ |